Literature DB >> 22190670

The hazards of randomized phase II trials.

P N Lara, M W Redman.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22190670     DOI： 10.1093/annonc/mdr567

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

Review 1.  Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells.

Authors:  Eduardo Marbán
Journal:  Mayo Clin Proc       Date:  2014-06       Impact factor: 7.616

2.  Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

Authors:  Mary W Redman; Bryan H Goldman; Michael LeBlanc; Anne Schott; Laurence H Baker
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531

Review 3.  The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Authors:  Samuel A Funt; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2016-02-03       Impact factor: 12.531

4.  Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Authors:  Tanios S Bekaii-Saab; Fang-Shu Ou; Daniel H Ahn; Patrick M Boland; Kristen K Ciombor; Erica N Heying; Travis J Dockter; Nisha L Jacobs; Boris C Pasche; James M Cleary; Jeffrey P Meyers; Rodwige J Desnoyers; Jeannine S McCune; Katrina Pedersen; Afsaneh Barzi; E Gabriela Chiorean; Jeffrey Sloan; Mario E Lacouture; Heinz-Josef Lenz; Axel Grothey
Journal:  Lancet Oncol       Date:  2019-06-28       Impact factor: 54.433

5.  Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project.

Authors:  William J Meurer; Laurie Legocki; Samkeliso Mawocha; Shirley M Frederiksen; Timothy C Guetterman; William Barsan; Roger Lewis; Donald Berry; Michael Fetters
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

Review 6.  Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement.

Authors:  Michael R Rosen; Robert J Myerburg; Darrel P Francis; Graham D Cole; Eduardo Marbán
Journal:  J Am Coll Cardiol       Date:  2014-09-02       Impact factor: 24.094

Review 7.  Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.

Authors:  Jaykaran Charan; Tea Reljic; Ambuj Kumar
Journal:  Indian J Pharmacol       Date:  2016 Mar-Apr       Impact factor: 1.200

Review 8.  The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.

Authors:  Pedro C Barata; Moshe C Ornstein; Jorge A Garcia
Journal:  J Kidney Cancer VHL       Date:  2017-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.